CD82, and CD63 in thyroid cancer.

  • Authors: Zhouxun Chen, Tarek Mustafa, Bogusz Trojanowicz, Michael Brauckhoff, Oliver Gimm, Cornelia Schmutzler, Josef Köhrle, Hans-Jürgen Holzhausen, Astrid Kehlen, Thomas Klonisch, Rainer Finke, Henning Dralle, Cuong Hoang-Vu
  • View Affiliations

  • Published online on: Friday, October 1, 2004
  • Pages: 517-544
  • DOI: 10.3892/ijmm.14.4.517

Abstract

CD82 (KAI1) and CD63 (ME491) are highly glycosylated proteins which belong to the transmembrane 4 superfamily (TM4SF). CD82 has been implicated as a possible prostate cancer metastasis suppressor gene, whereas CD63 is involved in the progression of human melanoma cancer. Down-regulation of both CD82 and CD63 expression has been associated with the metastatic potential of several solid tumors. Currently, information is lacking on the role of CD82 and CD63 during thyroid carcinogenesis. The aim of this study was to determine whether the expression of CD82 and CD63 is a useful prognostic indicator in patients with thyroid carcinoma. The expression of CD82 and CD63 was analysed by reverse transcriptase-PCR (RT-PCR) and immunohistochemistry in benign goiter (n=12) and 75 primary thyroid carcinoma tissue specimens (PTC: 33, FTC: 24, UTC: 18) out of which 36 were non-metastasized primary tumors and 39 were metastasized tumors (regional lymph node and/or distant metastases). All of the benign goiter tissues showed CD82 expression. By contrast, a significant decrease in CD82 mRNA and protein levels was detected in carcinoma tissues as compared to benign goiter tissues (p<0.001). A similar down-regulation was observed in metastasized tumor tissues when compared with non-metastasized tumors (all p<0.05). CD82 expression was correlated with pTNM status of differentiated and undifferentiated thyroid tumor and the pathologic stage of differentiated thyroid tumor. In contrast to CD82, CD63 mRNA and protein expression was unchanged in all thyroid carcinomas. Benign goiter tissues showed weak expression of CD63. There were no significant correlation between CD63 mRNA/protein expression and any clinical/pathological parameters. Our results support the hypothesis that down-regulation of CD82 expression may reflect an increased in vivo metastatic potential of thyroid cancer cells. CD82 may serve as a prognostic marker of metastasis in thyroid cancer. Constitutive expression of CD63 may indicate that this factor does not play a direct role in thyroid carcinogenesis.
Journal Cover

October 2004
Volume 14 Issue 4

Print ISSN: 1107-3756
Online ISSN:1791-244X

2013 Impact Factor: 1.88
Ranked #27/122 Medicine Research and Experimental
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Chen, Z., Mustafa, T., Trojanowicz, B., Brauckhoff, M., Gimm, O., Schmutzler, C., Köhrle, J., Holzhausen, H., Kehlen, A., Klonisch, T., Finke, R., Dralle, H., & Hoang-Vu, C. (2004). CD82, and CD63 in thyroid cancer.. International Journal of Molecular Medicine, 14(4), 517-544.
MLA
Chen, Mustafa, Trojanowicz, Brauckhoff, Gimm, Schmutzler, Köhrle, Holzhausen, Kehlen, Klonisch, Finke, Dralle, and Cuong Hoang-Vu. "CD82, and CD63 in thyroid cancer.." International Journal of Molecular Medicine International Journal of Molecular Medicine 14.4 (2004): 517-544.
Chicago
Chen, Mustafa, Trojanowicz, Brauckhoff, Gimm, Schmutzler, Köhrle, Holzhausen, Kehlen, Klonisch, Finke, Dralle, and Cuong Hoang-Vu. "CD82, and CD63 in thyroid cancer.." International Journal of Molecular Medicine International Journal of Molecular Medicine 14 no. 4 (2004): 517-544.